ReviewAlpha psychiatry2026
Histone Modifications in Psychiatry: From Canonical Marks to Neurotransmitter-Mediated Epigenetic Signatures.
Review in Alpha psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histone modifications have emerged as critical epigenetic regulators in the development and progression of mental disorders. This review synthesizes recent advances in the field, highlighting both canonical modifications, such as methylation, acetylation, and phosphorylation, as well as novel discoveries that link neurotransmitter signaling to chromatin regulation. In particular, neurotransmitter-mediated histone modifications, including serotonylation, dopaminylation, and histaminylation, represent a compelling new paradigm by which neuronal activity and environmental stimuli can induce lasting changes in gene expression. Aberrant histone modifications have been implicated in the risk, symptomatology, and treatment response of psychiatric conditions such as depression, bipolar disorder, and schizophrenia. Furthermore, therapeutic strategies that target histone-modifying enzymes, most notably histone deacetylase inhibitors, are being actively explored for their potential to restore epigenetic balance and improve clinical outcomes. A deeper understanding of the mechanistic diversity and disease specificity of histone modifications will be crucial for the development of precision epigenetic therapies in psychiatry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.